Masimo Corporation $MASI Shares Sold by Squarepoint Ops LLC

Squarepoint Ops LLC lessened its holdings in Masimo Corporation (NASDAQ:MASI) by 6.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 583,747 shares of the medical equipment provider’s stock after selling 37,185 shares during the period. Squarepoint Ops LLC owned approximately 1.09% of Masimo worth $75,922,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Global Retirement Partners LLC acquired a new position in shares of Masimo in the 4th quarter valued at $27,000. Los Angeles Capital Management LLC acquired a new position in shares of Masimo in the 4th quarter valued at $31,000. Rothschild Investment LLC lifted its stake in shares of Masimo by 12,950.0% in the 4th quarter. Rothschild Investment LLC now owns 261 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 259 shares during the last quarter. Torren Management LLC acquired a new position in shares of Masimo in the 4th quarter valued at $35,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Masimo in the 4th quarter valued at $38,000. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Price Performance

MASI opened at $179.95 on Tuesday. The stock’s 50-day moving average price is $178.72 and its 200 day moving average price is $160.89. Masimo Corporation has a 12-month low of $125.94 and a 12-month high of $179.99. The company has a current ratio of 2.68, a quick ratio of 1.45 and a debt-to-equity ratio of 0.56. The firm has a market cap of $9.42 billion, a price-to-earnings ratio of -17.07, a PEG ratio of 1.82 and a beta of 1.11.

Analyst Ratings Changes

Several brokerages have recently commented on MASI. Stifel Nicolaus set a $180.00 price target on Masimo in a research note on Tuesday, February 17th. Raymond James Financial lowered Masimo from an “outperform” rating to a “market perform” rating in a research note on Friday, March 27th. Weiss Ratings raised Masimo from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, May 6th. Wells Fargo & Company raised Masimo to a “hold” rating in a research note on Wednesday, March 18th. Finally, Wolfe Research lowered Masimo from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 19th. Nine analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $180.40.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.